Valeant teamed up with activist investor Bill Ackman's Pershing Square Capital Management LP to help drive the hostile takeover. Last week, Allergan, Pershing Square and Valeant agreed to hold a shareholder meeting on Dec. 18 about the US$54-billion takeover proposal.